Search Medical Condition
Please enter condition
Please choose location

Atrial Fibrillation Clinical Trials

A listing of Atrial Fibrillation medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (472) clinical trials

A Novel Healthcare Information Technology Tool to Improve Care in Patients With Atrial Fibrillation

This study is a prospective, observational study designed to evaluate the use of the Geneva Healthcare Patient Population Management platform to detect AF (atrial fibrillation) in patients with CIEDs (cardiovascular implantable electronic devices) in the emergency room setting, and assess the feasibility of sub-specialty cardiac electrophysiology (EP) care of these ...

Phase N/A

Comparison of the Ganglionated Plexi Activity in Patients With Different Forms of Atrial Fibrillation Guided by SUMO Technology

The purpose of this study is to compare DUA (discrete uptake accumulations) of mIBG activity in patients with different forms of atrial fibrillation and within a sub-group of healthy subjects.

Phase

Use of a High Density Mapping System to Complete Wide Area Circumferential Ablation of the Pulmonary Veins and Avoid Ostial Segmental Ablation

BACKGROUND Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia occurring in 1-2% of the general population. AF can be associated with debilitating symptoms and confers an increased risk of death, stroke, heart failure and hospitalization. As such there is a need for effective therapies for AF. In particularly ...

Phase N/A

Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation

This is a multicenter study in adult patients with AF and ESRD who are on hemodialysis and who have stroke risk factors making them candidates for oral anticoagulation. Patients will be randomized to apixaban versus warfarin, and will be treated for up to 15 months.

Phase

Edoxaban Treatment Versus Vitamin K Antagonist (VKA) in Patients With Atrial Fibrillation (AF) Undergoing Catheter Ablation

There are insufficient data on the safety and efficacy of edoxaban therapy in subjects with AF following catheter ablation. This phase 3b study is designed to evaluate the safety and to explore the efficacy of an edoxaban-based antithrombotic regimen versus a VKA-based antithrombotic regimen in subjects with AF following catheter ...

Phase

Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation (ENVISAGE-TAVI AF)

Use of Edoxaban in patients with atrial fibrillation (AF) and indication to chronic oral anticoagulation (OAC) after transcatheter aortic valve implantation (TAVI) Objective To assess the effect of Edoxaban versus vitamin K antagonist (VKA) on net adverse clinical events (NACE), i.e., the composite of all-cause death, myocardial infarction (MI), ischemic ...

Phase

Clinical Study for Workflow and Performance Evaluation of the THERMOCOOL SMARTTOUCH SF-5D System for Treating Symptomatic Paroxysmal AF (QDOT-Micro)

The purpose of this study is to evaluate the workflow and acute performance , during standard electrophysiology mapping and RF ablation procedures, of the THERMOCOOL SMARTTOUCH SF-5D catheter with temperature sensing capabilities and micro electrodes used in combination with the CARTO 3 Navigation System with THERMOCOOL SMARTTOUCH SF-5D-module.

Phase N/A

Edoxaban Treatment in Routine Clinical Practice for Patients With Atrial Fibrillation in Korea and Taiwan (ETNA-AF-KOR-TWN)

Edoxaban was approved by the Ministry of Food and Drug Safety (MFDS) in Korea (date: 25th, August 2015) for the reduction in the risk of stroke and systemic embolism in patients with NVAF, treatment of deep vein thrombosis (DVT) and pulmonary embolism. Edoxaban was approved by the Taiwan Food and ...

Phase N/A

Electrical Cardioversion of Recent Onset Atrial Fibrillation - Silent Thromboembolic Events Reverse Atrial Remodeling

Working plan This study will give information about the incidence of silent cerebral thrombo-embolic events in patients with recent onset AF, a population which is expected to consist mostly of paroxysmal AF patients. Patients with atrial fibrillation (AF) duration less than 48 hours and fulfilling inclusion and not exclusion criteria ...

Phase N/A

AMPLATZER LAA Occluder Post Approval Study (PAS)

The AMPLATZER LAA Occluder device will be clinically evaluated through this post approval study. This is a prospective, multicenter, non-randomized observational post-approval study, on patients who will undergo an implant of the AMPLATZER LAA Occluder.

Phase N/A